Mutations and Common Polymorphisms in ADAMTS13 Gene Responsible for Von Willebrand Factor-cleaving Protease Activity
Overview
Authors
Affiliations
von Willebrand factor (VWF) is synthesized primarily in vascular endothelial cells and secreted into the plasma as unusually large VWF multimers. Normally, these multimers are quickly degraded into smaller forms by a plasma metalloproteinase, VWF-cleaving protease (VWF-CP). Decreases in the activity of this enzyme result in congenital and acquired thrombotic thrombocytopenic purpura (TTP). The human VWF-CP has recently been purified. Cloning of the corresponding cDNA revealed that the 1,427-aa polypeptide is a member of the ADAMTS gene family, termed ADAMTS13. Twelve rare mutations in this gene have been identified in patients with congenital TTP. Here, we report missense and nonsense mutations in two Japanese families with Upshaw-Schulman syndrome, congenital TTP with neonatal onset and frequent relapses. The comparison of individual ADAMTS13 genotypes and plasma VWF-CP activities indicated that the R268P, Q449stop, and C508Y mutations abrogated activity of the enzyme, whereas the P475S mutant retained low but significant activity. The effects of these mutations were further confirmed by expression analysis in HeLa cells. Recombinant VWF-CP containing either the R268P or C508Y mutations was not secreted from cells. In contrast, Q449stop and P475S mutants were normally secreted but demonstrated minimal activity. Genotype analysis of 364 Japanese subjects revealed that P475S is heterozygous in 9.6% of individuals, suggesting that approximately 10% of the Japanese population possesses reduced VWF-CP activity. We report on a single-nucleotide polymorphism associated with alterations in VWF-CP activity; it will be important to assess this single-nucleotide polymorphism as a risk factor for thrombotic disorders.
Animal models for thrombotic thrombocytopenic purpura: a narrative review.
Zheng L, Zheng X Ann Blood. 2024; 8.
PMID: 39148951 PMC: 11326488. DOI: 10.21037/aob-22-18.
Novel mechanisms of action of emerging therapies of hereditary thrombotic thrombocytopenic purpura.
Zheng X Expert Rev Hematol. 2024; 17(7):341-351.
PMID: 38752747 PMC: 11209763. DOI: 10.1080/17474086.2024.2356763.
How We Interpret Thrombosis with Thrombocytopenia Syndrome?.
Yamada S, Asakura H Int J Mol Sci. 2024; 25(9).
PMID: 38732176 PMC: 11084439. DOI: 10.3390/ijms25094956.
Wang X, Hao X, Dai C, Ding Y, Xiong L, Deng J Curr Med Sci. 2023; 43(5):1043-1050.
PMID: 37815743 DOI: 10.1007/s11596-023-2793-7.
Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023.
Matsumoto M, Miyakawa Y, Kokame K, Ueda Y, Wada H, Higasa S Int J Hematol. 2023; 118(5):529-546.
PMID: 37689812 PMC: 10615956. DOI: 10.1007/s12185-023-03657-0.